Skip to main content

Table 2 Adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Toxicity All grades Grade 3 or higher
Hematologic
 Anemia 101 (97.1%) 18 (17.3%)
 Neutropenia 69 (66.3%) 44 (42.3%)
 Leukopenia 69 (66.3%) 25 (24.0%)
 Thrombocytopenia 73 (70.2%) 2 (1.9%)
Nonhematologic
 Febrile neutropenia    6 (5.8%)
 Anorexia 43 (41.3%) 1 (1.0%)
 Fatigue 89 (85.6%) 0 (0.0%)
 Stomatitis 32 (30.8%) 0 (0.0%)
 Diarrhea 63 (60.6%) 3 (2.9%)
 Constipation 50 (48.1%) 0 (0.0%)
 Nausea 71 (68.3%) 0 (0.0%)
 PN 93 (89.4%) 11 (10.6%)
 Edema in limbs 29 (27.9%) 0 (0.0%)
  1. PN peripheral sensory neuropathy